2022 RUSH Medical College Alumni Awards

Biennially at Reunion events since 2003, the RUSH Medical College Alumni Association awards three Distinguished Alumni awards and the Campbell Alumni Service Award. Congratulations to the 2022 RUSH Medical College alumni award recipients. Recipients will be honored at All Alumni Weekend.

2022 Distinguished Alumni Award in Medical Research and Education

Jamie Von Roenn, MD '80, FASCO, GME

Image

Jamie H. Von Roenn, MD, currently serves as the vice president of Education, Science and Professional Development for the American Society of Clinical Oncology, or ASCO. Before joining ASCO’s staff in September 2013, she was a professor in the Department of Medicine at Northwestern University’s Feinberg School of Medicine and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. She served as co-director of its Cancer Control Program and as the medical director of the Palliative Care and Home Hospice Program at NMH, which she helped establish in the mid-1980s. She spearheaded the integration of palliative medicine into oncology care across the continuum of the cancer experience at Northwestern University nationally and internationally. She received an award from ASCO for this work.

Von Roenn has served in leadership positions in multiple national organizations. She is a past member of the board of directors of ASCO and the board of directors of the American Academy of Hospice and Palliative Medicine. She has also served as chair of multiple committees for ASCO and as a member of the American Board of Internal Medicine’s Medical Oncology Subspecialty Board. She was a coach and mentor in an international leadership development program, which included onsite and distance mentoring in low- and middle-resource countries. She has served as one of the co-chairs and faculty for the American Association of Cancer Research-American Society of Clinical Oncology Clinical Trials Workshop, the AIDS Malignancy Consortium and the ECOG AIDS Malignancy committee. Von Roenn remains actively involved in education and mentoring.
 

2022 Distinguished Alumni Award in Clinical Excellence

John Segreti, MD '80, GME

Image

John Segreti, MD, received his medical degree from RUSH Medical College in 1980. He completed his residency in Internal Medicine at Rush-Presbyterian-St. Luke’s Medical Center in 1983 and completed a fellowship in infectious diseases in 1986. He has been awarded teaching awards from RUSH University Medical Center’s Department of Medicine and was recently recognized as one of the top infectious disease doctors in the Chicago area by Chicago Magazine.

Segreti is currently a professor in the Department of Internal Medicine at RUSH Medical College. He is also a hospital epidemiologist and chair of the Infection Prevention and Control committees at RUSH University Medical Center and RUSH Oak Park Hospital.
 

2022 Distinguished Alumni Award in Leadership, Service or Innovation

Larry J. Goodman, MD, GME

Image

Larry J. Goodman, MD, became interim president of RUSH University in July 2022. He previously was CEO of RUSH University Medical Center from February 2002 to May 2019, serving a dual role as president of RUSH University until February 2019. Goodman was also the first CEO of the RUSH University System for Health, serving in this role from March 2017 to May 2019. He holds the academic rank of professor of internal medicine and is the University’s James A. Campbell, MD, Distinguished Service Professor.

Under Goodman’s leadership, RUSH University Medical Center became nationally recognized for excellence in patient care, breakthrough research, community engagement and technological innovation, while returning to and maintaining a position of solid financial strength.

Before his appointments as CEO, Goodman served as senior vice president of medical affairs and dean of RUSH Medical College. From 1995 to 1998, Goodman was the medical director of John H. Stroger, Jr. Hospital of Cook County. Before that appointment, Goodman served at RUSH University Medical Center as an infectious disease specialist, associate dean of RUSH Medical College and assistant dean of clinical curriculum.

Goodman is a 1976 graduate of the University of Michigan Medical School, and he completed a residency in internal medicine and a fellowship in infectious disease at RUSH University Medical Center. During his fellowship, he served as the chief medical resident before joining the faculty.

Goodman serves on the board of the Civic Consulting Alliance, which provides pro bono consulting services to the city of Chicago and Cook County in areas of greatest public need. Goodman also serves on the board of the Sentry Insurance Co.
 

2022 Campbell Alumni Service Award

Philip D. Bonomi, MD, GME

Image

Philip D. Bonomi, MD, is the professor emeritus in the Division of Hematology, Oncology and Cell Therapy at RUSH University Medical Center. Bonomi received his medical degree from the University of Illinois College of Medicine in Chicago in 1970. He also completed a Master of Science degree at theGraduate College at the University of Illinois. He finished his residency in internal medicine at Geisinger Medical Center in Danville, Pennsylvania, in 1975. Bonomi had a break in his residency and served as a lieutenant in the U.S. Navy from 1972 to 1974. Upon completing his internal medicine residency, he accepted a fellowship in oncology at Rush-Presbyterian-St. Luke’s Medical Center in Chicago. He has remained at RUSH University Medical Center, where he was the director of the Section of Medical Oncology and the Division of Hematology, Oncology and Cell Therapy from 1992 to 2016. He was the Alice Pirie Wirtz professor of Medicine from 1989 until 2022 and was granted professor emeritus status at RUSH University Medical Center on July 1.  

Bonomi has been involved in lung cancer research for more than four decades. He served on the test writing committee for the American Board of Internal Medicine for six years. He was a member of the Scientific Advisory Board for the LUNGevity Foundation from its inception in 2002 until March 2022, served on the FDA’s committee for Lung Cancer Blueprint in 2020 and was a member of the International Association for the Study of Lung Cancer. He served as the chairman of the Thoracic Committee for the Eastern Cooperative Oncology Group from 1985 to 1986. 

Bonomi and his colleagues at RUSH were among the first investigators to show that treating stage 3 non-small cell lung cancer patients with chest radiation and concurrent chemotherapy was feasible. They also showed that surgery following chemoradiation was associated with lower chances of morbidity and mortality. While surgical treatment following chest radiation and chemotherapy is done less frequently in stage 3 non-small cell lung cancer patients now, treatment with concurrent chest radiation and chemotherapy continues to be the primary treatment. He was also involved in the early development of carboplatin and paclitaxel, two chemotherapeutic agents still used to treat non-small cell lung cancer. He was a leader in the first trial that showed that erlotinib, an oral non-chemotherapeutic agent, produced dramatic remissions in non-small cell lung cancer patients. A large trial showed improved survival in non-small cell lung cancer patients whose cancer was progressing after treatment with chemotherapy and led to the FDA approval of the first oral targeted therapy for lung cancer patients. Bonomi and his RUSH colleagues were the first investigators to show that weight gain occurred during treatment with chemotherapy and simultaneous chest radiation in some advanced lung cancer patients and that this group of patients survived significantly longer. He also participated in large pharmaceutical database studies, which confirmed that study. 

More recently, he worked with LUNGevity scientific board members, the FDA, pharmaceutical companies and other clinical investigators to relax clinical trial eligibility criteria and streamline logistics in clinical trials to increase patient access to clinical trials. Following his retirement from clinical practice, he continues working with RUSH’s lung cancer research team to study the relationship between cachexia, biomarkers, weight gain during treatment and outcomes in lung cancer patients. He is particularly interested in studying these relationships in lung cancer patients receiving immunotherapy.